progress

T-cell lymphoma: autologous or allogeneic transplant?
Francine Foss
3:48
Ibrutinib in treatment for refractory or relapsed CLL
George Follows
3:38
Closing the gap between basic and clinical CLL research
Emili Montserrat
1:41
A new era in CLL
Federico Caligaris-Cappio
1:01
Using models to predict progression in follicular lymphoma
Sarah Huet
4:10
Exciting times for Waldenström’s macroglobulinemia: new treatments and tools
Steven Treon
4:25
Recent developments in the mutational landscape and molecular basis of AML
Charles Craddock
1:24
Escalating doses and improving outcomes in cutaneous T-cell lymphomas
Martine Bagot
Encouraging data from the RAY trial 3-year follow-up
Simon Rule
2:41
ICML 2017 session on the biosimilar rituximab: challenges and data
Christian Buske
1:29
Are combination therapies more effective for the treatment of relapsed refractory CLL?
Ian Flinn
4:09
What does the CLL forum data tell us?
George Follows
2:23
An overview of the lymphoma landscape from BSH 2017
Robert Marcus
10:43
COMy 2017: Day 1 discussion on progress in multiple myeloma, patient advocacy and drug costs
Arnon Nagler et al.
16:48
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
1:49
Prospect of new therapies for AML
Mhairi Copland
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals